Showing 5631-5640 of 8207 results for "".
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- New Survey: Rosacea Inflicts Physical Discomforthttps://practicaldermatology.com/news/20120925-new_survey_rosacea_inflicts_physical_discomfort/2459731/A recent survey conducted by the National Rosacea Society (NRS) shows that significant physical discomfort often accompanies the visible signs of rosacea. In the survey of 1,709 patients with rosacea, nearly 93 percent said they had experienced physical discomfort as a result of the disorder. A burn
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),
- Colorescience's Diane Ranger to Receive Innovators in Dermatology Award at CSF 2012https://practicaldermatology.com/news/20120917-coloresciences_diane_ranger_to_receive_innovators_in_dermatology_award_at_csf_2012/2459738/Diane Ranger, Founder and President of Colorescience Mineral Makeup, and acknowledged inventor of mineral makeup, will receive the "Innovators in Dermatology Award" at Cosmetic Surgery F
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- ASDS Annual Meeting Sessions Announced, Early Registration Discounthttps://practicaldermatology.com/news/20120808-asds_annual_meeting_sessions_announced_early_registration_discount/2459754/The 2012 Annual Meeting of the American Society for Dermatologic Surgery (ASDS) will be held from October 11 to 14 in Atlanta, GA. The 65-plus scientific and educational sessions are divided into four comprehensive curriculum tracks: co
- Zein Obagi, MD To Direct 24th Ultimate Skin Health Symposiumhttps://practicaldermatology.com/news/20120807-zein_obagi_md_to_direct_24th_ultimate_skin_health_symposium/2459755/Zein E. Obagi, MD was named director of the 24th Ultimate Skin Health Symposium, a three-day skin rejuvenation program taking place at the Montage Hotel, Beverly Hills, CA, from November 9-11, 2012. Key topics of the symposium will i
- DASIL Announces Inaugural Congresshttps://practicaldermatology.com/news/20120725-dasil_announces_inaugural_congress/2459763/The Dermatologic & Aesthetic Surgery International League (DASIL), headquartered in Chicago, Illinois, is hosting its first annual DASIL Congress, to be held on the island of Malta, from October 31 to November 4, 2012. This international dermatol
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33